OCX: OncoCyte Corporation Operating Margin

OncoCyte - graphic logo of issuer OCX

OncoCyte Corporation (OCX) generates revenue through the sale of innovative oncology tests and the laboratory analysis of biomarkers. The operating profit margin confirms the efficiency of this model, reaching -608.40. The business relies on B2B partnerships and Medicare approval, creating a closed monitoring ecosystem. Simultaneously, the company is implementing ESG standards by digitizing reporting and optimizing medical waste disposal to protect the environment.

oncocyte.com (OCX): Operating Return on Sales from 07/04/2022 to 06/18/2025

Metric breakdowns and analytics for OncoCyte (OCX)

Fundamental valuation:oncocyte.com, OCX
Brand item of oncocyte.com

This metric measures the share of operating profit in revenue, reflecting the efficiency of cost management before accounting for debt load and taxes. For OncoCyte Corporation (OCX), this metric is critical, as regulatory barriers and raw material supply disruptions directly increase costs, which the annual operating margin clearly captures, signaling the fundamental stability of the business.